Track maridebart cafraglutide in Peptimes™
Maridebart cafraglutide (AMG 133) is an investigational human monoclonal antibody against the GIP receptor, joined to two copies of a GLP-1 analogue peptide, according to FDA's substance registry. (Source: FDA's substance registry (GSRS).)
Is maridebart cafraglutide FDA-approved?
No. Maridebart cafraglutide is investigational: it's being studied in clinical trials and isn't FDA-approved for any use.
Maridebart cafraglutide
Also: MariTide, AMG 133
- Status label in the Peptimes Library
- Phase 3 Trials
- Routes in Peptimes
- Subcutaneous
- Updated
- 1 Nov 2026
US regulatory status
FDA status
Not FDA-approved for any use. Drugs@FDA lists no application with maridebart cafraglutide as an active ingredient.
Source: Drugs@FDA, checked 1 Nov 2026
Investigational
Yes.
Source: ClinicalTrials.gov, checked 1 Nov 2026
What studies have looked at
Each point says who or what was studied and what the study reported, with its source and the date we checked it. These are findings from the sources cited, not advice or a promise of any result.
- In humans
MARITIME-1, a double-blind, placebo-controlled Phase 3 trial in 3,853 adults with obesity, or overweight without type 2 diabetes, measures the change in body weight at week 72. Enrolment is complete; no results yet.
Source: NCT06858839, checked 1 Nov 2026
How to track it in Peptimes
Add maridebart cafraglutide in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Phase 3 Trials”, which describes its investigational status. It isn’t an approval.
- Logging: the amount you took and how you feel.
- Injection sites: each dose records the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell maridebart cafraglutide or any other compound.
More sources
- NIH, ClinicalTrials.gov, MARITIME-1 (NCT06858839), checked 1 Nov 2026: a Phase 3 study sponsored by Amgen, active, not recruiting.
- NIH, ClinicalTrials.gov, studies of maridebart cafraglutide, checked 1 Nov 2026: registered studies, all sponsored by Amgen, including Phase 3 studies.
- FDA, Drugs@FDA, searched 1 Nov 2026: no application lists maridebart cafraglutide as an active ingredient.
- FDA, Global Substance Registration System, Maridebart cafraglutide, checked 1 Nov 2026: an anti-GIP receptor antibody joined to a GLP-1 analogue, and the code AMG 133.